Subanesthetic Dose of Esketamine Improves the Sedative and Analgesic Effects of Dexmedetomidine and Remifentanil in Liposuction Anesthesia

Esketamine Improves the Sedative and Analgesic Effects of Dexmedetomidine and Remifentanil in Liposuction Anesthesia

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400080363

Enrollment

Unknown

Registered

2024-01-26

Start date

2024-01-30

Completion date

Unknown

Last updated

2024-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sedative and Analgesic Anesthesia

Interventions

Esketamine group:Esketamine

Control group:None

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Males or females aged 18-60 years (2)The ASA I ~ II grade (3)Sign an informed consent form with the patient before surgery

Exclusion criteria

Exclusion criteria: (1) acute and/or chronic pain before surgery (2) taking analgesic drugs within 48 hours of surgery (3) history of congenital heart disease, arrhythmia, or hypertension (4) severe lung disease in the past month (5) contraindications or allergy to esketamine (6) history of severe mental or neurological diseases, drug or psychotropic drug abuse (7) cognitive dysfunction or inability to communicate

Design outcomes

Primary

Measure	Time frame
Patient and surgical team satisfaction scores;	—

Secondary

Measure	Time frame
Postoperative sleep quality scores;Postoperative anxiety and depression scores;Intraoperative vital signs;Intraoperative drugs consumption;Perioperative adverse reactions;	—

Countries

China

Contacts

Public ContactWei Linxin

Plastic Surgery Hospital, Chinese Academy of Medical Sciences

weilx3934@sina.com+86 155 2200 2357

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026